Purchase

Recombinant Mouse EGFR protein (rFc Tag) (HPLC verified)

Species

Mouse

Purity

>90 %, SDS-PAGE
>90%, SEC-HPLC

Tag

rFc Tag

Activity

not tested

Cat no : Eg3498


Product Information

Purity >90 %, SDS-PAGE
>90%, SEC-HPLC
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Not tested
Expression HEK293-derived Mouse EGFR protein Leu25-Ser647 (Accession# Q01279) with a rabbit IgG Fc tag at the C-terminus.
GeneID 13649
Accession Q01279
PredictedSize 95.6 kDa
SDS-PAGE 100-120 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

EGFR (Epidermal Growth Factor Receptor) is a receptor for epithelial growth factor (EGF) cell proliferation and signaling and belongs to the ErbB receptor family, also known as HER1 or ErbB1.It is a glycoprotein, a tyrosine kinase-type receptor, with a cell-membrane penetration, and a molecular weight of approximately 170 kDa. EGFR EGFR is located on the surface of the cell membrane and is activated by binding to ligands, including EGF and TGFα. Upon activation, EGFR is converted from a monomer to a dimer, and activation activates its intracellular kinase pathways, including the MAPK, Akt, and JNK pathways, which induces cellular proliferation. Mutations in or overexpression of EGFR generally lead to tumorigenesis, and have been associated with the development of a variety of cancers, including lung cancer, anogenital carcinoma, and polymorphic glioblastoma, and glioblastoma multiforme, among others. (PMID: 37036745)

References:

1. Voldborg BR, et al. Ann Oncol. 1997;8(12):1197-206. 2. Talukdar S, et al. Adv Cancer Res. 2020;147:161-188. 3. Sapmaz A, et al. Oncotarget. 2023;14:297-301.